| # | Title | Journal | Year | Citations |
|---|
| 1 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | New England Journal of Medicine | 2015 | 6,773 |
| 2 | Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial | Lancet, The | 2004 | 1,561 |
| 3 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) | Lancet, The | 2017 | 1,032 |
| 4 | Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future | Lancet, The | 2020 | 260 |
| 5 | Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma | JAMA Oncology | 2015 | 201 |
| 6 | Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer | Journal of Clinical Oncology | 2003 | 197 |
| 7 | Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report | Journal of Thoracic Oncology | 2019 | 189 |
| 8 | Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies | Nature Reviews Clinical Oncology | 2014 | 185 |
| 9 | Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination | European Radiology | 2008 | 145 |
| 10 | Imaging in Metastatic Renal Cell Carcinoma | American Journal of Roentgenology | 2007 | 102 |
| 11 | Prognostic Value of Intrinsic Subtypes in Hormone Receptor–Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib | JAMA Oncology | 2016 | 96 |
| 12 | Protein kinase C inhibitors | Current Oncology Reports | 2002 | 95 |
| 13 | Genome‐wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target | Journal of Pathology | 2012 | 92 |
| 14 | Endometrial stromal sarcomas | Gynecologic Oncology | 1990 | 88 |
| 15 | Mammography in the assessment of response to medical treatment of large primary breast cancer | Clinical Radiology | 1993 | 82 |
| 16 | The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma | Annals of Oncology | 2007 | 75 |
| 17 | A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer | Annals of Oncology | 2014 | 71 |
| 18 | Ovarian cancer | European Journal of Cancer | 2002 | 70 |
| 19 | Management of in-transit metastases from cutaneous malignant melanoma | British Journal of Surgery | 2004 | 66 |
| 20 | Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma | Cancer Management and Research | 2012 | 50 |
| 21 | The role of percutaneous nephrostomy in malignant urinary tract obstruction | Clinical Radiology | 1993 | 36 |
| 22 | Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance | Annals of Surgical Oncology | 2019 | 36 |
| 23 | Establishing an EGFR mutation screening service for non-small cell lung cancer – Sample quality criteria and candidate histological predictors | European Journal of Cancer | 2012 | 34 |
| 24 | A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial | Journal of Thoracic Oncology | 2020 | 34 |
| 25 | Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum | BMC Cancer | 2015 | 32 |
| 26 | Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane | Annals of Oncology | 2013 | 31 |
| 27 | Imaging in oncology—over a century of advances | Nature Reviews Clinical Oncology | 2012 | 25 |
| 28 | Response evaluation in mesothelioma: Beyond RECIST | Lung Cancer | 2015 | 25 |
| 29 | Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies | Expert Opinion on Pharmacotherapy | 2017 | 24 |
| 30 | Fine Needle Aspiration Cytodiagnosis As A Pre-Requisite For Primary Medical Treatment of Breast Cancer | Cytopathology | 1991 | 22 |
| 31 | BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC) | Heliyon | 2018 | 21 |
| 32 | Non-surgical aspects of ovarian cancer | Lancet, The | 1994 | 17 |
| 33 | Catheter fracture: a rare complication of totally implantable venous devices | Breast | 2003 | 13 |
| 34 | Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts | Radiotherapy and Oncology | 2020 | 13 |
| 35 | Chemotherapy for recurrent ovarian cancer | Lancet, The | 2003 | 12 |
| 36 | Vinorelbine and Infusional 5-fluorouracil in Anthracycline and Taxane Pre-treated Metastatic Breast Cancer | Clinical Oncology | 2008 | 8 |
| 37 | Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity | Lancet Oncology, The | 2005 | 7 |
| 38 | Bridging the age gap in breast cancer: impact of omission of breast cancer surgery in older women with oestrogen receptor-positive early breast cancer on quality-of-life outcomes | British Journal of Surgery | 2021 | 7 |
| 39 | A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer | Clinical Cancer Research | 2020 | 6 |
| 40 | How to become a breast cancer specialist in 2018: The point of view of the second cohort of the Certificate of Competence in Breast Cancer (CCB2) | Breast | 2019 | 5 |
| 41 | Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy | European Urology Focus | 2020 | 5 |
| 42 | Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC) | Annals of Oncology | 2016 | 4 |
| 43 | Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme | ESMO Open | 2018 | 4 |
| 44 | Paraneoplastic syndrome: Subacute cerebellar degeneration in Hodgkin's disease | Leukemia and Lymphoma | 2007 | 3 |
| 45 | Financial burden and financial toxicity in patients with colorectal, gastro-oesophageal, and pancreatobiliary cancers: A UK study | Journal of Cancer Policy | 2020 | 3 |
| 46 | Endobronchial metastases from renal cell carcinoma: A late manifestation of the disease with an increasing incidence | BJU International | 2012 | 2 |
| 47 | An adult with common acute lymphoblastic leukaemia (C-ALL) presenting with skin infiltration | British Journal of Dermatology | 1991 | 1 |
| 48 | Malignant pleural mesothelioma: Two cases in first degree relatives | Lung Cancer | 2007 | 1 |
| 49 | The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer | Lung Cancer | 2010 | 1 |
| 50 | Combination chemotherapy for ovarian cancer-lessons not yet learned? | Current Oncology Reports | 2002 | 0 |
